Entheon Biomedical is a biotech company focussed on the development of psychedelic medicines for addiction disorders. The Company’s research and development pipeline revolves around DMT.
The Company listed on the CSE on 12 November, 2020.
We spoke to Entheon’s CEO, Timothy Ko, about his goals for the Company, as well as his personal background and story.
“We are very confident in what we’re developing and so we are eager to validate our assumptions in a clinical setting. The number of people dying and suffering from substance use disorder is immense and unfathomable.”